Table 45a:
Reference Case Analysis Disaggregated Results, Migraine
| Outcome | nVNS in addition to standard care, mean (95% CrI) | Standard care alone, mean (95%CrI) | Mean difference (95% CrI)a,b |
|---|---|---|---|
| Cost outcomes | |||
| Total cost per person per year | $9,200 ($8,892 to $9,507) | $2,877 ($2,818 to $2,934) | $6,324 ($6,016 to $6,642)a |
| Cost of nVNS | $6,372 | $0 | $6,372 |
| Cost of acute medication | $456 | $504 | -$48b |
| Cost of preventive medication | $2,189 | $2,189 | $0 |
| Cost of monitoring | $184 | $184 | $0 |
| Effectiveness outcomes | |||
| Number of migraine days per year | 69.84 (61 to 76) | 74.44 (67 to 81) | -5.60d |
| Total QALYs | 0.7876 (0.7595 to 0.8144) | 0.7809 (0.7533 to 0.8076) | 0.0066 (-0.0053 to 0.0186)d |
Abbreviations: Crl, credible interval; ICER, incremental cost-effectiveness ratio; nVNS; noninvasive vagus nerve stimulation; QALY, quality-adjusted life-year.
a
Results may appear inexact due to rounding.
b
Negative costs indicate savings.